Approval · Notice of Compliance 784 · 2002
EXELON: Notice of Compliance 784
Issued February 6, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 784
- Date
- February 6, 2002
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form: oral solution
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON | 02245240 | Marketed |
Medicinal ingredients
- RIVASTIGMINE HYDROGEN TARTRATE 2 MG per ML